Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, July 1999, p. 489-493, Vol. 6, No. 4
Division of Infectious
Diseases1 and Division of
Gastroenterology,
Received 28 October 1998/Returned for modification 8 February
1999/Accepted 15 March 1999
Several different families of vacuolating toxin (vacA)
alleles are present in Helicobacter pylori, and they encode
products with differing functional activities. H. pylori
strains containing certain types of vacA alleles have been
associated with an increased risk for peptic ulcer disease. In this
study, we tested serum samples and gastric juice from 19 H. pylori-negative and 39 H. pylori-positive patients
for enzyme-linked immunosorbent assay reactivity with two different
types of VacA antigens (types s1/m1 and s2/m2), which were purified
from H. pylori 60190 and 86-338, respectively. Both
antigens were recognized better by serum immunoglobulin G (IgG) from
H. pylori-positive persons than by serum IgG from H. pylori-negative persons (P < 0.01). The s1/m1
VacA antigen was better recognized by sera from patients carrying
vacA type s1/m1 strains than by sera from patients carrying
vacA type s2/m2 or s1/m2 strains (P < 0.01). Conversely, the s2/m2 VacA antigen was better recognized by sera
from patients carrying type s2/m2 or s1/m2 strains (P = 0.03). Serum IgG anti-VacA antibodies were present more frequently in
patients carrying type s1/m1 strains than in other H. pylori-positive patients (P = 0.0002). In
addition, the highest levels of IgA anti-VacA antibodies were detected
in the gastric juice of patients carrying type s1/m1 strains. These data indicate that different VacA isoforms have distinct antigenic properties and that multiple forms of VacA elicit antibody responses in
H. pylori-positive humans.
More than half of the world's human
population is colonized with the gram-negative gastric bacterium
Helicobacter pylori. Colonization with this organism
consistently gives rise to infiltration of the gastric mucosa by immune
and phagocytic cells and is associated with an increased risk for
development of peptic ulceration, distal gastric adenocarcinoma, and
gastric lymphoma (1, 2, 14).
Many H. pylori strains secrete a toxin (VacA) that induces
cytoplasmic vacuolation in mammalian cell lines in vitro (6-8, 17). In addition to this action, VacA interferes with
normal maturation and trafficking of lysosomal enzymes (27),
disrupts antigen presentation by T cells (20), and increases
the permeability of polarized epithelial cell monolayers
(23). VacA is initially translated as a 140-kDa protoxin,
which then undergoes proteolytic processing to yield a mature ~90-kDa
secreted toxin (12, 29). These VacA monomers assemble into
complex six- or seven-sided oligomeric structures (11, 18).
Sequence analysis has revealed that there is considerable allelic
variation among vacA genes from different H. pylori strains. Diversity is particularly striking in the region
of vacA that encodes the N-terminal signal sequence and in
the midregion of vacA. Two different families of
vacA alleles (s1 and s2) have been recognized based on
analysis of the signal sequence region, and two families of
vacA alleles (m1 and m2), which are about 70% identical in
nucleotide sequences within a 0.7-kb region, have been recognized based
on analysis of the midregion (3, 12). H. pylori
strains that produce vacuolation of HeLa cells in vitro usually contain
type s1/m1 or occasionally type s1/m2 vacA alleles, whereas
strains with type s2/m2 vacA alleles lack detectable
cytotoxin activity for HeLa cells (3). Some strains with
type s1/m2 vacA alleles produce vacuolation of RK-13 cells but not HeLa cells, which suggests that VacA sequence differences confer cell type-specific activities (21). Several studies
performed in the United States and Europe have shown that the risk of
peptic ulcer disease is higher among persons colonized with H. pylori strains containing type s1 vacA alleles than
among those with strains containing type s2 vacA alleles
(3, 28, 30).
The considerable diversity in the deduced amino acid sequences of
different vacA products suggests that there might be marked antigenic diversity among VacA proteins from different strains. In
previous studies (9, 10), it has been shown that about 50%
of H. pylori-positive persons in the United States produce serum immunoglobulin G (IgG) antibodies that react with a purified VacA
antigen from H. pylori 60190 (a type s1/m1 VacA antigen). However, other types of VacA proteins have not yet been tested for
possible utility as antigens in serodiagnostic assays. In addition, it
is not known whether the vacA genotypes of H. pylori strains influence anti-VacA immunoglobulin responses.
Therefore, in this study we used two different purified VacA antigens
in enzyme-linked immunosorbent assays (ELISAs) to analyze specific serum and gastric juice anti-VacA responses in patients who were colonized with H. pylori strains of known vacA
genotype. We report here that both type s1/m1 and type s2/m2 forms of
VacA are useful antigens in serologic assays and that these two
isoforms have distinguishable antigenic properties.
Purification of H. pylori VacA antigens.
Two
different H. pylori strains (60190 and 86-338) were selected
as the sources for VacA antigens used in this study. H. pylori 86-338 was isolated from a patient with nonulcer dyspepsia
in the United States, and H. pylori 60190 (ATCC 49503) was
isolated from a patient in the United Kingdom. The vacA
sequence of strain 60190 (GenBank U05676) is the prototype for the
s1/m1 family of vacA alleles (12). PCR-based
typing and partial sequence analysis of vacA from strain
86-338 indicate that this strain contains a type s2/m2 vacA
allele (3, 15). Both strains produce high-molecular-mass
VacA oligomers with similar ultrastructural morphologies
(11). Both strains were cultured in sulfite-free brucella
broth containing 0.5% charcoal, and proteins in the broth culture
supernatants were concentrated by precipitation with a 50% saturated
solution of ammonium sulfate. VacA oligomers then were purified by gel
filtration chromatography with a Superose 6 HR 16/50 column, as
described previously (8, 11). Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and silver
staining demonstrated isolation of ~90-kDa VacA bands from both
strains (Fig. 1), and both VacA bands
reacted with polyclonal rabbit anti-VacA serum (8) (data not
shown). The VacA band from strain 86-338 was slightly larger than the
VacA band from strain 60190, which is consistent with previous analysis
of a type s2/m2 VacA protein from a different H. pylori
strain (3). Supernatant from H. pylori 60190 yielded about 10-fold-higher quantities of purified VacA than
supernatant from strain 86-338 (15), which accounts for the
increased representation of trace contaminant bands in preparations of
the latter VacA protein (Fig. 1, lane b).
Collection of H. pylori isolates, sera, and gastric
juice specimens.
We studied 58 human patients (mean age, 55.9 ± 12.6 years) who underwent routine upper gastrointestinal endoscopy
at the VA Medical Center in Nashville, Tenn., between February 1993 and May 1995 (Table 1). This group of
patients has been described in several previous studies (3, 4,
24). Two biopsy specimens from each patient, taken from the
gastric antrum and gastric corpus, were cultured under microaerobic
conditions at 37°C for isolation of H. pylori.
Unstimulated gastric juice aspirates, obtained after an overnight fast,
were collected from each patient and immediately separated into
aliquots, which were stored at
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Detection of Anti-VacA Antibody Responses in Serum
and Gastric Juice Samples Using Type s1/m1 and s2/m2
Helicobacter pylori VacA Antigens

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (24K):
[in a new window]
FIG. 1.
Purification of type s1/m1 and s2/m2 VacA antigens. VacA
was purified from broth culture supernatants of H. pylori
60190 and 86-338 (lanes a and b, respectively), and the two
preparations (standardized by protein concentration) were analyzed by
SDS-PAGE and silver staining. Yields of VacA from strain 60190 were
about 10-fold higher than those from strain 86-338; therefore, the VacA
preparation from the latter strain was concentrated 10-fold by
ultrafiltration with a Centricon-30 device (Amicon) prior to
SDS-PAGE.
20°C. Gastric biopsy specimens from
each patient were examined and histologic parameters were graded, as
described previously (4). All patients classified as
colonized by H. pylori (n = 39) had a
positive gastric mucosal culture for H. pylori, and all were
seropositive by an ELISA that tests for the presence of IgG antibodies
to a pool of antigens from several different sonicated H. pylori strains (25). IgG antibody results in this ELISA
are reported as optical density (OD) ratios, based on comparison with a
pool of sera from H. pylori-negative children
(13). The vacA genotypes of H. pylori
isolates were determined by a PCR-based typing method, as described
previously (3). All patients classified as not colonized
(n = 19) had a negative H. pylori culture, a
negative rapid urease test, and no evidence of H. pylori on
histologic examination and were seronegative by an ELISA that tested
for antibodies to sonicated H. pylori. In addition to being
tested for reactivity with sonicated H. pylori, sera were
tested for ELISA reactivity with purified recombinant CagA, as
described previously (5). A total of 21 of the 39 patients
colonized with H. pylori, and 3 of the noncolonized patients were reported to have past or present peptic ulcer disease.
TABLE 1.
Characteristics of the study population of 58 dyspeptic
patients from Tennessee
ELISA for detection of antibodies to VacA in human sera. Serum samples were tested for reactivity with purified VacA proteins in ELISAs. Plates (96-well, Immulon 2; Dynatech, Alexandria, Va.) were coated with VacA antigens (approximately 25 ng/well) in carbonate buffer and stored overnight at room temperature. Sera were diluted in phosphate-buffered saline and were incubated with the bound antigens for 1 h at 37°C. After the plates were washed, peroxidase-conjugated anti-human IgG or anti-human IgA (Biosource International, Camarillo, Calif.) was added and the conjugate dilutions were incubated for 1 h. Antigen-antibody complexes were resolved with 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) (1 mg/ml) in McIlvain's buffer (consisting of titrations of 0.2 M Na2HPO4 plus 0.1 M citric acid, pH 4.6) (25). The optimal concentrations of patient sera and peroxidase-conjugated anti-human antibodies, determined by checkerboard titrations (25), were a serum dilution of 1:100, an IgG conjugate dilution of 1:4,000, and an IgA conjugate dilution of 1:2,000. OD values were determined with an MRX ELISA reader (Dynatech) at dual wavelengths (405 and 490 nm). OD values were linear in a range from 0 to 2.5. Each serum sample was tested in duplicate.
ELISA for detection of antibodies to VacA in human gastric juice. Gastric juice samples were first mixed (1:1 [vol/vol]) with a buffer containing 100 mM Tris (pH 7.6), 60 mM sodium chloride, 0.2% sodium azide, 0.05 U of aprotinin protease inhibitor (Sigma, St. Louis, Mo.) per ml, and 2 mM tetrasodium EDTA (33). This procedure consistently resulted in neutralization of the gastric juice samples; i.e., pH >6.8. Neutralized gastric juice samples were diluted 1:4 with Dulbecco's phosphate-buffered saline (Gibco-BRL) containing 2.5% bovine serum albumin, and 100-µl aliquots were added to wells of ELISA plates that had been coated with purified VacA antigens (25 ng/well). After the plates were incubated at 37°C for 1 h, biotin-conjugated goat anti-human IgA (Sigma), diluted 1:1,000, was added to the wells for 1 h at 37°C. Avidin-conjugated alkaline phosphatase (Sigma), diluted 1:1,000, was added for 1 h, followed by substrate solution (1 mg of P-nitrophenyl phosphate per ml in 0.1 M diethylanolamine-HCl, pH 9.8) for 15 min. OD values were determined as described above.
Statistical analysis. Distributions of ELISA OD values (mean ± standard error of the mean) were compared by using Student's t test for independent variables.
| |
RESULTS |
|---|
|
|
|---|
Serum IgG and IgA responses to VacA.
Serum and gastric juice
specimens were collected from 58 patients, of whom 39 (67.1%) were
classified as H. pylori positive and 19 were classified as
H. pylori negative (Table 1). The vacA genotypes
of the 39 H. pylori isolates were classified as type s1/m1
(n = 19), s1/m2 (n = 12), or s2/m2
(n = 8). Sera from the 58 patients were tested for the
presence of IgG and IgA anti-VacA antibodies in two different ELISAs,
which used either type s1/m1 or s2/m2 VacA antigens. Sera from the 39 persons colonized with H. pylori demonstrated significantly
greater IgG and IgA reactivity with the type s1/m1 VacA antigen from
strain 60190 than did sera from the 19 noncolonized persons (Table
2). Among the 39 patients carrying
H. pylori, there was no significant association between levels of anti-VacA IgG antibodies and levels of IgG antibodies to
H. pylori whole-cell sonicates (not shown). Sera from
H. pylori-colonized patients demonstrated significantly
greater IgG reactivity with the type s2/m2 VacA antigen from strain
86-338 than did sera from noncolonized patients (Table 2). However,
there were no significant differences in IgA reactivity to the s2/m2
VacA antigen.
|
Gastric juice IgA responses to VacA.
In the next series of
experiments, we sought to determine whether anti-VacA antibodies could
be detected in human gastric juice. Since preliminary studies indicated
that gastric juice samples from H. pylori-positive patients
contain IgA but minimal IgG antibodies to H. pylori
sonicates (26), only gastric juice anti-VacA IgA responses
were analyzed. The type s1/m1 VacA antigen was recognized significantly
more strongly by gastric juice IgA from H. pylori-colonized
persons than by gastric juice IgA from H. pylori-negative
persons (P = 0.002), and as expected, gastric juice
from patients carrying vacA type s1/m1 strains yielded the highest reactivity (Table 3). Reactivity
to the s2/m2 antigen was higher for gastric juice from H. pylori-positive patients colonized with vacA type s1/m1
strains than for gastric juice from H. pylori-negative
patients (P = 0.02); the differences in reactivity of
gastric juice from s1/m2, s2/m2, and H. pylori-negative patient groups were not statistically significant. Thus, there are
differences in the patterns of serum and gastric juice reactivity to
s1/m1 and s2/m2 VacA antigens (compare Tables 2 and 3). Interestingly, among H. pylori-positive patients, levels of gastric juice
IgA antibodies to H. pylori sonicate antigens and to
purified VacA were significantly associated, and this relationship was
detected with both VacA antigens (r = 0.52 and 0.61 for
assays using type s1/m1 and s2/m2 VacA antigens, respectively;
P
0.001). In summary, these data are consistent with
the production of secretory IgA antibodies to VacA in the gastric
mucosa of H. pylori-colonized persons.
|
Relationship between vacA genotype, gastric histology, and gastric juice pH. As reported previously (4), patients colonized with type s1/m1 vacA-containing strains of H. pylori had higher scores for epithelial degeneration and gastric mucosal inflammation than did patients carrying H. pylori with type s2/m2 strains. However, there was no evidence that the magnitude of the humoral immune response to specific VacA antigens was a determinant of tissue injury or inflammation (data not shown). In addition, the occurrence of peptic ulceration was unrelated to the presence or absence of an anti-VacA antibody response.
| |
DISCUSSION |
|---|
|
|
|---|
The initial classification of vacA alleles into several major families was based on analysis of H. pylori strains isolated from patients in the United States (3). Subsequent analysis has confirmed the existence of these major families of vacA alleles in H. pylori strains isolated from patients throughout the world and has led to the identification of vacA subfamilies that predominate in certain geographic regions (16, 22, 28, 31, 32). Interestingly, nearly all H. pylori strains isolated from patients in Asia or developing countries contain type s1 vacA alleles (16, 22, 31, 32). The deduced amino acid sequences of type s1/m1 and s2/m2 VacA proteins are quite different from each other (3), and the results of this study suggest that these isoforms also differ in antigenic properties. Thus, it seems likely that regions of maximum VacA sequence diversity may correspond to surface-exposed epitopes.
Previous studies (9, 10) have demonstrated that about 50% of H. pylori-positive persons in the United States possess serum antibodies that react in an ELISA with purified VacA from H. pylori 60190 (a type s1/m1 antigen). One interpretation of these results is that these patients were colonized with strains that produce VacA antigens closely related to the type s1/m1 VacA antigen used in the ELISA. In agreement with this explanation, the current study indicates that 84% of patients colonized with type s1/m1 strains possess serum IgG anti-VacA antibodies detectable in an ELISA that uses the type s1/m1 VacA antigen from H. pylori 60190. Of the 20 patients in this study who were colonized with strains containing either s2/m2 or s1/m2 vacA alleles, only 5 (25%) had detectable serum IgG anti-VacA antibodies. Anti-VacA antibodies in the latter 5 patients reacted relatively more strongly in an ELISA with a type s2/m2 VacA antigen than in one with a type s1/m1 antigen, but there was clearly cross-reactivity.
The results of this study indicate that strains producing type s1/m1 forms of VacA are more likely to elicit production of serum anti-VacA antibodies than are H. pylori strains producing alternate forms. Similarly, gastric juice anti-VacA IgA responses are detected most commonly in patients harboring H. pylori strains producing type s1/m1 VacA proteins. There are several possible explanations for these differences. First, strains of H. pylori containing type s1/m1 vacA alleles typically produce and secrete higher levels of VacA in vitro than do strains containing alternate alleles (3, 8, 15), and if similar differences exist in vivo, this could account for the observed pattern of serologic responses. Alternatively, type s1/m1 VacA may be more highly immunogenic than other forms. Finally, s1/m1 strains have been associated with higher levels of gastric epithelial injury than other forms (4), and this may be associated with increased entry of VacA into the gastric mucosa, where antigen recognition probably occurs.
Since in this study, humoral immune responses to VacA were best detected in assays using homologous VacA antigens, the use of multiple VacA antigens may be desirable if VacA is to be used as a component of diagnostic assays for the detection of H. pylori infection. If only one antigen is to be used, assays that use a type s1/m1 antigen rather than a type s2/m2 antigen are recommended, since they seem to have greater sensitivity. Immunization of mice with a type s1/m1 VacA antigen has been reported to confer protective immunity only against H. pylori strains expressing homologous types of VacA (19). Thus, if VacA is to be used as a component of an H. pylori vaccine, the use of both type s1/m1 and s2/m2 isoforms may yield an increased level of protection.
| |
ACKNOWLEDGMENTS |
|---|
We thank Beverly Hosse for technical assistance and Kyi Tham for providing histologic data.
This study was supported in part by NIH grant AI-39657 and by the Medical Research Service of the Department of Veterans Affairs.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Infectious Diseases, A3310 MCN, Vanderbilt University School of Medicine, Nashville, TN 37232. Phone: (615) 322-2035. Fax: (615) 343-6160. E-mail: COVERTL{at}ctrvax.vanderbilt.edu.
Present address: Division of Gastroenterology, University Hospital,
Queen's Medical Centre, Nottingham, England.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Anonymous. 1994. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. Helicobacter pylori in peptic ulcer disease. JAMA 272:65-69[Medline]. |
| 2. | Anonymous. 1994. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr. Eval. Carcinog. Risks Hum. 61:177-240[Medline]. |
| 3. |
Atherton, J. C.,
P. Cao,
R. M. Peek, Jr.,
M. K. R. Tummuru,
M. J. Blaser, and T. L. Cover.
1995.
Mosaicism in vacuolating cytotoxin alleles of H. pylori: association of specific vacA types with cytotoxin production and peptic ulceration.
J. Biol. Chem.
270:17771-17777 |
| 4. | Atherton, J. C., R. M. Peek, Jr., K. T. Tham, T. L. Cover, and M. J. Blaser. 1997. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 112:92-99[Medline]. |
| 5. |
Blaser, M. J.,
G. I. Perez-Perez,
H. Kleanthous,
T. L. Cover,
R. M. Peek,
P. H. Chyou,
G. N. Stemmermann, and A. Nomura.
1995.
Infection with H. pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.
Cancer Res.
55:2111-2115 |
| 6. | Cover, T. L. 1996. The vacuolating cytotoxin of Helicobacter pylori. Mol. Microbiol. 20:241-246[Medline]. |
| 7. | Cover, T. L., D. E. Berg, and M. J. Blaser. 1997. VacA and the cag pathogenicity island of H. pylori, p. 75-90. In P. B. Ernst, P. Michetti, and P. D. Smith (ed.), "The immunobiology of H. pylori: from pathogenesis to prevention." Lippincott-Raven Publishers, Philadelphia, Pa. |
| 8. |
Cover, T. L., and M. J. Blaser.
1992.
Purification and characterization of the vacuolating toxin from Helicobacter pylori.
J. Biol. Chem.
267:10570-10575 |
| 9. |
Cover, T. L.,
P. Cao,
C. D. Lind,
K. T. Tham, and M. J. Blaser.
1993.
Correlation between vacuolating cytotoxin production by Helicobacter pylori isolates in vitro and in vivo.
Infect. Immun.
61:5008-5012 |
| 10. | Cover, T. L., P. Cao, U. K. Murthy, M. S. Sipple, and M. J. Blaser. 1992. Serum neutralizing antibody response to the vacuolating cytotoxin of Helicobacter pylori. J. Clin. Investig. 90:913-918. |
| 11. |
Cover, T. L.,
P. I. Hanson, and J. E. Heuser.
1997.
Acid-induced dissociation of VacA, the Helicobacter pylori vacuolating cytotoxin, reveals its pattern of assembly.
J. Cell Biol.
138:759-769 |
| 12. |
Cover, T. L.,
M. K. R. Tummuru,
P. Cao,
S. A. Thompson, and M. J. Blaser.
1994.
Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains.
J. Biol. Chem.
269:10566-10573 |
| 13. | Drumm, B., G. I. Perez-Perez, M. J. Blaser, and P. M. Sherman. 1990. Intrafamilial clustering of Helicobacter pylori infection. N. Engl. J. Med. 322:359-363[Abstract]. |
| 14. | Dunn, B. E., H. Cohen, and M. J. Blaser. 1997. Helicobacter pylori. Clin. Microbiol. Rev. 10:720-741[Abstract]. |
| 15. |
Forsyth, M. H.,
J. C. Atherton,
M. J. Blaser, and T. L. Cover.
1998.
Heterogeneity in levels of vacuolating cytotoxin gene (vacA) transcription among Helicobacter pylori strains.
Infect. Immun.
66:3088-3094 |
| 16. | Ito, Y., T. Azuma, S. Ito, H. Miyaji, M. Hirai, Y. Yamazaki, F. Sato, T. Kato, Y. Kohli, and M. Kuriyama. 1997. Analysis and typing of the vacA gene from cagA-positive strains of Helicobacter pylori isolated in Japan. J. Clin. Microbiol. 35:1710-1714[Abstract]. |
| 17. | Leunk, R. D., P. T. Johnson, B. C. David, W. G. Kraft, and D. R. Morgan. 1988. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J. Med. Microbiol. 26:93-99[Abstract]. |
| 18. |
Lupetti, P.,
J. E. Heuser,
R. Manetti,
P. Massari,
S. Lanzavecchia,
P. L. Bellon,
R. Dallai,
R. Rappuoli, and J. L. Telford.
1996.
Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin.
J. Cell Biol.
133:801-807 |
| 19. |
Marchetti, M.,
B. Arico,
D. Burroni,
N. Figura,
R. Rappuoli, and P. Ghiara.
1995.
Development of a mouse model of Helicobacter pylori infection that mimics human disease.
Science
267:1655-1658 |
| 20. | Molinari, M., M. Salio, C. Galli, N. Norais, R. Rappuoli, A. Lanzavecchia, and C. Montecucco. 1998. Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VacA. J. Exp. Med. 87:135-140. |
| 21. |
Pagliaccia, C.,
M. de Bernard,
P. Lupetti,
J. Xuhuai,
D. Burroni,
T. L. Cover,
E. Papini,
R. Rappuoli,
J. L. Telford, and J.-M. Reyrat.
1998.
The m2 form of the Helicobacter pylori cytotoxin has cell type-specific vacuolating activity.
Proc. Natl. Acad. Sci. USA
95:10212-10217 |
| 22. | Pan, Z.-J., D. E. Berg, R. W. M. van der Hulst, W.-W. Su, A. Raudonikiene, S.-D. Xiao, J. Dankert, G. N. J. Tytgat, and A. van der Ende. 1998. Prevalence of vacuolating cytotoxin production and distribution of distinct vacA alleles in Helicobacter pylori from China. J. Infect. Dis. 178:220-226[Medline]. |
| 23. | Papini, E., B. Satin, N. Norais, M. de Bernard, J. L. Telford, R. Rappuoli, and C. Montecucco. 1998. Selective increase of the permeability of polarized epithelial cell monolayers by Helicobacter pylori vacuolating toxin. J. Clin. Investig. 102:813-820[Medline]. |
| 24. | Peek, R. M., G. G. Miller, K. T. Tham, G. I. Perez-Perez, X. Zhao, J. C. Atherton, and M. J. Blaser. 1995. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab. Investig. 71:760-770. |
| 25. | Perez-Perez, G. I., B. M. Dworkin, J. E. Chodos, and M. J. Blaser. 1988. Campylobacter pylori antibodies in humans. Ann. Intern. Med. 109:11-17. |
| 26. | Perez-Perez, G. I., K. T. Tham, R. M. Peek, J. C. Atherton, and M. J. Blaser. 1994. Not all Helicobacter pylori-infected persons produce specific IgA in gastric juice. Gastroenterology 112:A1061. |
| 27. |
Satin, B.,
N. Norais,
J. Telford,
R. Rappuoli,
M. Murgia,
C. Montecucco, and E. Papini.
1997.
Effect of Helicobacter pylori vacuolating toxin on maturation and extracellular release of procathepsin D and on epidermal growth factor degradation.
J. Biol. Chem.
272:25022-25028 |
| 28. |
Strobel, S.,
S. Bereswill,
P. Balig,
P. Allgaier,
H.-G. Sonntag, and M. Kist.
1998.
Identification and analysis of a new vacA genotype variant of Helicobacter pylori in different patient groups in Germany.
J. Clin. Microbiol.
36:1285-1289 |
| 29. |
Telford, J. L.,
P. Ghiara,
M. Dell-Orco,
M. Comanducci,
D. Burroni,
M. Bugnoli,
M. F. Tecce,
S. Censini,
A. Covacci,
Z. Xiang,
E. Papini,
C. Montecucco,
L. Parente, and R. Rappuoli.
1994.
Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease.
J. Exp. Med.
179:1653-1658 |
| 30. |
van Doorn, L. J.,
C. Figueiredo,
R. Rossau,
G. Jannes,
M. van Asbroeck,
J. C. Sousa,
F. Carneiro, and W. G. V. Quint.
1998.
Typing of Helicobacter pylori vacA gene and detection of cagA gene by PCR and reverse hybridization.
J. Clin. Microbiol.
36:1271-1276 |
| 31. |
van Doorn, L.-J.,
C. Figueiredo,
R. Sanna,
S. Pena,
P. Midolo,
E. K. W. Ng,
J. C. Atherton,
M. J. Blaser, and W. G. V. Quint.
1998.
Expanding allelic diversity of Helicobacter pylori vacA.
J. Clin. Microbiol.
36:2597-2603 |
| 32. | Wang, H.-J., C.-H. Kuo, A. A. M. Yeh, P. C. L. Chang, and W.-C. Wang. 1998. Vacuolating toxin production in clinical isolates of Helicobacter pylori with different vacA genotypes. J. Infect. Dis. 178:207-212[Medline]. |
| 33. | Wirth, H. P., P. Vogt, R. Ammann, and J. Altorfer. 1993. IgA antibodies against Helicobacter pylori in gastric secretions: gastric secretory immune response or salivary contamination? Schweiz. Med. Wochenschr. 123:1106-1110[Medline]. |
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |